2018
TREX1 Mutation Causing Autosomal Dominant Thrombotic Microangiopathy and CKD—A Novel Presentation
Gulati A, Bale AE, Dykas DJ, Bia MJ, Danovitch GM, Moeckel GW, Somlo S, Dahl NK. TREX1 Mutation Causing Autosomal Dominant Thrombotic Microangiopathy and CKD—A Novel Presentation. American Journal Of Kidney Diseases 2018, 72: 895-899. PMID: 29941221, DOI: 10.1053/j.ajkd.2018.05.006.Peer-Reviewed Original ResearchConceptsRenal thrombotic microangiopathyThrombotic microangiopathyTREX1 mutationsRetinal microangiopathyChronic kidney diseaseRepair exonuclease 1Whole-exome sequencingSignificant brainSymptomatic brainTREX1 variantsKidney involvementClinical presentationKidney diseaseCerebral leukodystrophyComplement dysregulationMicroangiopathyClinical importanceDiverse causesComplement regulationNovel presentationSubstantial proportionBrainSignificant proportionGenetic determinantsCause
2017
Slow Rise in Serum Creatinine Level in a Kidney Transplant Recipient 3 Years Post-Transplant
Bia MJ. Slow Rise in Serum Creatinine Level in a Kidney Transplant Recipient 3 Years Post-Transplant. Clinical Journal Of The American Society Of Nephrology 2017, 12: 1692-1694. PMID: 28336817, PMCID: PMC5628727, DOI: 10.2215/cjn.12691216.Peer-Reviewed Original Research
2009
HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin
Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin. Journal Of Clinical Gastroenterology 2009, 43: 477-481. PMID: 19142165, PMCID: PMC3715868, DOI: 10.1097/mcg.0b013e318180803a.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseHepatitis C virusCombination therapyRenal diseasePosttreatment rateSide effectsSerious adverse side effectsDose of ribavirinNon-ESRD patientsSafe therapeutic optionEarly virologic responseProspective observational studyMonths of treatmentStage renal diseaseCases of anemiaInitial response rateLength of treatmentInterferon α-2aAdverse side effectsPO weeklyVirologic responseESRD patientsHCV infectionESRD populationHCV response
2006
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period
Formica RN, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrology Dialysis Transplantation 2006, 21: 1389-1394. PMID: 16431893, DOI: 10.1093/ndt/gfk058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmlodipineBlood Pressure DeterminationChi-Square DistributionDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansHypertensionKidney Failure, ChronicKidney TransplantationLosartanMaleMiddle AgedProbabilityRisk AssessmentSeverity of Illness IndexTreatment OutcomeConceptsRenal transplant recipientsPost-transplant periodEarly post-transplant periodARB useUse of ARBInitial therapyCCB groupImmediate post-transplant periodPost-transplant erythrocytosisPost-transplant hypertensionRisk of hyperkalaemiaPost-transplant managementSerum creatinine levelsChronic kidney diseaseII receptor blockersCalcium channel blockersNumber of patientsAldosterone systemARB groupKidney transplantationRenal transplantationTransplant recipientsCreatinine levelsRenal functionBlood pressure